logo
AAT Bioquest

Mca-YVADAPK(Dnp)-OH

Mca-YVADAPK(Dnp)-OH is a fluorogenic peptide substrate for detecting caspase-1/interleukin-converting enzyme (ICE) and angiotensin I-converting enzyme-2 (ACE-2). Its N-terminal contains a highly fluorescent 7-methoxycoumarin (MCA) fluorophore that is efficiently quenched by non-fluorescent 2,4-dinitrophenyl group on lysine residue via fluorescence resonance energy transfer (dark FRET). It can be used to measure the activities of caspase-1/interleukin-converting enzyme (ICE) and angiotensin I-converting enzyme-2 (ACE-2) that are capable of cleaving an amide bond between the fluorescent group (MCA) and the quencher group (DNP), resulting an increase in fluorescence.
Product Image
Product Image
Gallery Image 1
Ordering information
Price
Unit size
Catalog Number13557
Quantity
Add to cart
Additional ordering information
Telephone1-800-990-8053
Fax1-800-609-2943
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
ShippingStandard overnight for United States, inquire for international
Request quotation
Physical properties
Molecular weight1145.15
SolventDMSO
Spectral properties
Correction Factor (280 nm)0.3
Excitation (nm)322
Emission (nm)381
Storage, safety and handling
H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
StorageFreeze (< -15 °C); Minimize light exposure
UNSPSC12171501
Spectrum
References
View all 50 references: Citation Explorer
Marked Up-Regulation of ACE2 in Hearts of Patients With Obstructive Hypertrophic Cardiomyopathy: Implications for SARS-CoV-2-Mediated COVID-19.
Authors: Bos, J Martijn and Hebl, Virginia B and Oberg, Ann L and Sun, Zhifu and Herman, Daniel S and Teekakirikul, Polakit and Seidman, Jonathan G and Seidman, Christine E and Dos Remedios, Cristobal G and Maleszewski, Joseph J and Schaff, Hartzell V and Dearani, Joseph A and Noseworthy, Peter A and Friedman, Paul A and Ommen, Steve R and Brozovich, Frank V and Ackerman, Michael J
Journal: Mayo Clinic proceedings (2020): 1354-1368
In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression.
Authors: Sinha, Sanju and Cheng, Kuoyuan and Schäffer, Alejandro A and Aldape, Kenneth and Schiff, Eyal and Ruppin, Eytan
Journal: Molecular systems biology (2020): e9628
Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection.
Authors: Kong, Qi and Xiang, Zhiguang and Wu, Yue and Gu, Yu and Guo, Jianguo and Geng, Fei
Journal: Molecular cancer (2020): 80
Mass Spectrometry Analysis of Newly Emerging Coronavirus HCoV-19 Spike Protein and Human ACE2 Reveals Camouflaging Glycans and Unique Post-Translational Modifications.
Authors: Sun, Zeyu and Ren, Keyi and Zhang, Xing and Chen, Jinghua and Jiang, Zhengyi and Jiang, Jing and Ji, Feiyang and Ouyang, Xiaoxi and Li, Lanjuan
Journal: Engineering (Beijing, China) (2020)
SARS-CoV-2 Infections and ACE2: Clinical Outcomes Linked With Increased Morbidity and Mortality in Individuals With Diabetes.
Authors: Obukhov, Alexander G and Stevens, Bruce R and Prasad, Ram and Li Calzi, Sergio and Boulton, Michael E and Raizada, Mohan K and Oudit, Gavin Y and Grant, Maria B
Journal: Diabetes (2020): 1875-1886